The lower the KI67, the better. the higher the KI67, the worse the effect of chemotherapy, the higher the risk of recurrence and metastasis, and the poorer the prognosis. KI67 is a marker reflecting tumor activity, localized in the cytosolic nucleus, and is a biomarker for many malignant tumors, as assessed by immunohistochemical findings in postoperative pathology. A higher KI67 indicates a higher percentage of cells in the proliferative cycle, faster tumor growth, poor chemotherapy and a higher chance of recurrence. Moreover, lesions with higher KI67 are more prone to systemic metastasis, systemic spread and poor prognosis. Clinical assessment of malignant tumors should be combined with the patient’s age, type of malignant tumor, other immunohistochemical indexes and other aspects, patients should maintain a good mindset during the treatment process, and actively cooperate with the doctor’s treatment in order to prolong the survival period.